# A Study of SKB315 in Patients With Advanced Solid Tumors

> **NCT05367635** · PHASE1 · RECRUITING · sponsor: **Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.** · enrollment: 246 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** SKB315 for injection
- **DRUG:** Drug: Tagitanlimab Drug: Capecitabine

## Key facts

- **NCT ID:** NCT05367635
- **Lead sponsor:** Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-16
- **Primary completion:** 2026-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 246 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05367635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05367635, "A Study of SKB315 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05367635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*